“Reversi-type virologic failure” involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline-Reference-Cited by-同舟云学术

“Reversi-type virologic failure” involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline

Published:2017-04-19 Issue:13 Volume:47 Page:1397-1407
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Uchida Yoshihito¹,Kouyama Jun-ichi¹,Naiki Kayoko¹,Sugawara Kayoko¹,Inao Mie¹,Imai Yukinori¹,Nakayama Nobuaki¹,Mochida Satoshi¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Faculty of Medicine; Saitama Medical University; Saitama Japan

Funder

the Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development (AMED)

Saitama Medical University Hospital

Ochiai Memorial Foundation

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12882/fullpdf

Reference13 articles.

1. Daclatasvir plus asnaprevir for chronic HCV genotype 1b infection;Kumada;Hepatology,2014

2. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial;Mizokami;Lancet Infect Dis,2015

3. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis;Kumada;Hepatology,2015

4. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial;Zeuzem;Ann Intern Med,2015

5. Resistance analyses of japanese hepatitis C-infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies;Mizokami;J Viral Hepat,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region;South of Russia: ecology, development;2024-04-07

2. Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase;Expert Opinion on Investigational Drugs;2024-01-02

3. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice;Biochemical and Biophysical Research Communications;2021-06

4. Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus;Hepatology Research;2020-04

5. A case of genotype‐3b hepatitis C virus in which the whole genome was successfully analyzed using third‐generation nanopore sequencing;Hepatology Research;2019-06-13